Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7720717 | 0.94 | — | — | |
| SCHEMBL3431746 | 0.89 | TBXAS1 (0.66) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL28062565 | 0.87 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL503743 | 0.87 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL3362075 | 0.85 | — | — | |
| SCHEMBL9777191 | 0.84 | TBXAS1 (0.60) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL9846593 | 0.81 | TBXAS1 (0.58) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL285224 | 0.79 | TERT (0.59) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL3958988 | 0.79 | TBXAS1 (0.61) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL89096 | 0.79 | TBXAS1 (0.56) | TBXAS1TERTALOX15TAAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745002-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| EP-1745002-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105725-A1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | TBXAS1 381/4885TERT 3298/4885ALOX15 438/4885 |
| US-20080114036-A1 | Novel Compounds, Their Preparations And Use | PPARG, PPARD, GPR119 | TBXAS1 194/4885TERT 3210/4885ALOX15 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.